文献速递治疗药物监测与药物基因组学特殊人群用药

美国多种族人群中基于循证药物基因组信息的处方药物暴露全国研究

A National Study Among Diverse US Populations of Exposure to Prescription Medications with Evidence-Based Pharmacogenomic Information.
PubMed 文献 · Clin Pharmacol Ther · 2025-03-03

该研究分析2014至2021年MEPS全国代表性数据中119,722名成人,评估具有可操作药物基因组(PGx)信息的药物处方暴露差异。结果显示61%被处方PGx药物,心血管疾病、高胆固醇、高血压和癌症患者更可能接受PGx处方,自报黑人相比白人PGx处方可能性更低(aIRR=0.92,95%CI 0.90,0.94),少数族裔在患病群体中暴露可能性亦更低。

要点

  • 61%的成人被处方至少一种具有可操作PGx信息的药物。
  • 心血管病、高胆固醇、高血压和癌症患者PGx处方可能性更高。
  • 自报黑人相比白人PGx处方可能性更低(aIRR=0.92,95%CI 0.90,0.94)。

核心结论

  • 全国代表性数据表明某些人群对基因组指导药物的暴露存在差异。
  • 基于处方触发的反应性PGx检测项目可能因处方差异而预期黑人群体代表性略低。
  • 基于临床指征/合并症的靶向抢先检测可能合理富集受益于基因型指导处方的患者。

研究设计与样本

  • 分析2014至2021年MEPS全国代表性成人处方数据,最终人群N=119,722(72%白人/20%黑人/4%亚裔/8%西班牙裔)。
  • PGx药物定义为FDA和CPIC指定具有科学证据支持的药物-基因关联的药物。
  • 主要结局为PGx处方,采用泊松回归调整所有其他相关协变量。

主要发现

  • 最终人群中61%被处方PGx药物,56%为女性,97%持有医疗保险。
  • 有私人保险(65%)或公共Medicaid/Medicare(32%)者比无保险者(3%)更可能接受PGx处方。
  • 心血管疾病aIRR=1.45(95%CI 1.41,1.48)、高胆固醇aIRR=1.37(95%CI 1.35,1.40)、高血压aIRR=1.14(95%CI 1.12,1.16)、癌症aIRR=1.02(95%CI 1.00,1.04)患者更可能接受PGx处方。
  • 自报黑人相比白人PGx处方可能性更低(aIRR=0.92,95%CI 0.90,0.94)。
  • 在患有健康条件的人群中, underrepresented群体(黑人、西班牙裔、亚裔)的PGx药物暴露可能性低于白人。

临床怎么用

  • 若实施基于处方触发的反应性PGx检测项目,需考虑处方差异可能导致黑人群体代表性不足。
  • 若实施靶向抢先PGx检测,可利用临床指征/合并症富集可能受益于基因型指导处方的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tailoring pharmacogenomic (PGx) implementation to diverse populations is vital to promoting health equity. We assessed prescriptions for medications with potentially actionable PGx information to identify patient characteristics associated with differential PGx medication exposure. We analyzed the nationally-representative MEPS dataset of adults who reported receiving prescriptions between 2014 and 2021. PGx medications include those the FDA and CPIC designate as having drug-gene associations supported by scientific evidence. With the primary outcome being PGx prescriptions, we performed Poisson regression adjusted for all other relevant covariates. In our final population (N = 119,722, 72% White/20% Black/4% Asian/8% Hispanic), 61% were prescribed a PGx medication, 56% were female, and 97% held health insurance coverage. Adults with private health insurance (65%) or public Medicaid/Medicare coverage (32%) were more likely to have PGx prescriptions than the uninsured (3%). Individuals with cardiovascular conditions [adjusted IRR (aIRR) = 1.45, 95% CI 1.41, 1.48], high cholesterol [aIRR = 1.37, 95% CI 1.35, 1.40], high blood pressure [aIRR = 1.14, 95% CI 1.12, 1.16], and cancer [aIRR = 1.02, 95% CI 1.00, 1.04] were more likely to receive PGx prescriptions. Self-reported Blacks were less likely than Whites to receive PGx medications [aIRR = 0.92, 95% CI 0.90, 0.94], and among those with health conditions, the likelihood of PGx medication exposure for underrepresented groups (Blacks, Hispanics, and Asians) was lower than for Whites. Our study using a comprehensive list of PGx medications in a nationally representative dataset indicates that certain populations are differentially exposed to genomically informed medications. This may suggest that if implementing a pharmacogenomics program based on reactive testing initiated by a prescription, a small underrepresentation of the Black population could be expected because of an underlying prescription disparity. Secondly, if implementing a pharmacogenomics program based on targeted preemptive testing, using clinical indication/comorbidity may be a reasonable way to enrich the population for prescriptions that would benefit from genotype tailoring.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Saulsberry L, Jameson JC, Gibbons RD, et al. A National Study Among Diverse US Populations of Exposure to Prescription Medications with Evidence-Based Pharmacogenomic Information. Clin Pharmacol Ther. 2025. PMID: 40033674. doi:10.1002/cpt.3617

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。